Vor Biopharma VOR Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vor Biopharma's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vor Biopharma's unrealized gains (losses) on available-for-sale securities?
- Vor Biopharma (VOR) reported unrealized gains (losses) on available-for-sale securities of -$747K in Q1 2026.
- How has Vor Biopharma's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Vor Biopharma's unrealized gains (losses) on available-for-sale securities decreased by 74800.0% year-over-year, from $1K to -$747K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the unrealized gains or losses on investment securities held by the company that are classified as available-for-sale. These changes are recorded directly in equity rather than through the income statement, reflecting market-driven fluctuations in the value of the company's treasury or investment portfolio. It provides insight into the volatility and performance of the company's liquid asset holdings.